AstronauTx exercises option from Saniona to acquire worldwide rights to neurological disease program under research collaboration

/in

Development candidate ATX0926 enters IND-enabling stage of development expanding AstronauTx’s pipeline of therapies targeting sleep biology Represents the successful outcome of a multi-year scientific collaboration between AstronauTx and Saniona Saniona receives shares in AstronauTx with a value of US$5 million London, UK and Copenhagen, Denmark, 10 August 2026 – Saniona (OMX: SANION), a clinical-stage biopharmaceutical company […]

Read more

AC Immune First Half 2026 Financial and Corporate Update

/in

Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term clinical results anticipated for H2 2026 Phase 2 VacSYn trial of ACI-7104 in Parkinson’s disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation Morphomer small molecule program […]

Read more

Simris Group Appoints Biotechnology Expert Dr. Tiffany J. Vora as Strategic Advisor

/in

Hammenhög, Sweden, July 28, 2026 — Simris Group AB (SIMRIS B) today announced the appointment of Dr. Tiffany J. Vora as a Strategic Advisor. Dr. Vora is a biotechnology scientist, entrepreneur, educator, and advisor with experience across molecular biology, genomics, biotechnology innovation, and drug discovery. Through her work with technology companies, startups, scientific organizations, and the broader innovation […]

Read more
xeltis

Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch

/in

New investor Horizon 3 Healthcare led the round, which was supported by the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders Builds on the €50m secured in 2025 and supports Xeltis’ next phase of clinical, regulatory and commercial execution Additional €20.5m provides the runway to finalize the ongoing US […]

Read more

NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

/in

Recommendation based on NEXUS data; Minoryx and Neuraxpharm expect European Commission approval by the end of this quarter Barcelona, Spain and Düsseldorf, Germany – 24 July, 2026 – Minoryx Therapeutics and Neuraxpharm Group, announce that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional […]

Read more
© Optimum Strategic Communications.